Clinical Experience: OMS ElectroImmunotherapy

OncoSec's ElectroImmunotherapy program uses the OncoSec Medical System (OMS) to deliver engineered DNA plasmid constructs that encode a specific cytokine. Cytokines play a vital role in regulating the body's immune system against bacteria, viruses and cancer cells. However, in the case of a cancerous tumor, the cancer cells have adapted systems to evade the anti-tumor processes regulated by cytokines. The OMS ElectroImmunotherapy treatment approach is intended to boost the patients immune system and re-estabilish the effectiveness of the anti-tumor processes regulated by cytokines, which results in a selective and potent treatment effect.

OncoSec's lead drug candidate for the ElectroImmunotherapy program is interleukin-12 (IL-12). While IL-12 immunotherapy is administered locally, initial evidence from a Phase 1 study suggests that the resulting immune response produces both a local and a systemic effect against cancerous cells. If this study can be further validated, OMS ElectroImmunotherapy using IL-12 would represent an important development in the treatment of both local and metastatic disease. A Phase 2 confirmatory study is planned for initiation by the end of 2011.